THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Kim Kelderman, President, Diagnostics and Genomics of Bio-Techne CorporationACD is rapidly becoming established as the leader in the C> space due to its novel method of tracking the bio-distribution of genetically modified cells in the tissue. “We are proud to offer Bio-Techne’s portfolio to meet the needs of the growing cell and gene therapy field. The RNAscope ISH assay enables the quantification of modified cells and genes in intact tissue, a unique capability that relies on the robust technology that has resulted in thousands of publications worldwide," states Kim Kelderman, President of Diagnostics and Genomics at Bio-Techne Corporation. The RNAscope assay can be used to detect CAR-positive cells within the tumor microenvironment (TME) to measure infiltration, activity, and T-cell activation and recruitment. Together with the diverse portfolio of Bio-Techne products, C> researchers are supported at every step of the workflow, from GMP grade reagents to transposon technology for CAR and TCR construct integration, to T-cell activation kits, to scalable cell culture systems, to CloudzTM -based cell selection technology.
At ACD, the Pharma Assay Services group has years of experience designing and executing studies for dozens of C> companies. Researchers who partner with Pharma Assay Services will receive on-demand access to the most specialized and technically experienced RNAscope hands of any CRO.
By partnering with our scientific experts for study design and data interpretation, our customers can be confident in the science, and actionable results can be in-hand in weeks rather than months.
We are proud to offer Bio-Techne’s portfolio to meet the needs of the growing cell and gene therapy field. The RNAscope ISH assay enables the quantification of modified cells and genes in intact tissue, a unique capability that relies on the robust technology that has resulted in thousands of publications worldwide.
In data presented by Bellicum at ASCO-GI in 2020, Bellicum partnered with ACD’s Pharma Assay Services to use RNAscope to evaluate biopsies collected from patients enrolled in Phase 1 of the BP-012 clinical trial in metastatic pancreatic cancer. RNAscope probes were designed to detect Bellicum’s GoCAR-T cell in solid tumors, and the assay was performed in biopsies taken at baseline and on-treatment. The RNAscope assay demonstrated clear infiltration of GoCAR-T cells in the solid tumors and concurrent evaluation of CD3-positive cells showed no difference in CD3-cell recruitment. This clearly shows the unique ability of RNAscope to visualize modified T-cells within the tumor, as well as the ability to concomitantly assess transduced versus untransduced T- cells recruited to the tumor. The RNAscope analysis was a crucial measure of GoCAR-T cell infiltration. It demonstrated a fundamentally new capability for cell therapy researchers to assess the biodistribution and persistence of modified T cells within tissues.
Today, ACD’s R&D team is continuing to expand the toolbox for spatial profiling of any target from any species in fixed frozen, fresh frozen and FFPE tissues. The BaseScope™ assay, for instance, can be used to distinguish codon-optimized transgenes from endogenous sequences. With the recent launch of the RNAscope HiPlex Assay, researchers can simultaneously detect up to twelve (12) RNA targets on a single slide, thus generating more data per sample without compromising the morphological features of the tissue. The HiPlex Assay utilizes ACD’s patented signal amplification and background suppression technology to deliver unique specificity and sensitivity with optimal signal generation.
Company
Advanced Cell Diagnostics
Management
Kim Kelderman, President, Diagnostics and Genomics of Bio-Techne Corporation
Description
ACD, a Bio-Techne brand, expands research tools for spatial genomics by combining molecular information with spatial context in one simple assay. The company provides a powerful new tool for visualizing and quantifying modified cells and genes in tissue through RNAscopeTM, an advanced in situ hybridization (ISH) technology. ACD is rapidly becoming established as the leader in the C> space due to its novel method of tracking the bio-distribution of genetically modified cells in the tissue. At ACD, the Pharma Assay Services group has years of experience designing and executing studies for dozens of C> companies. Researchers who partner with Pharma Assay Services will receive on-demand access to the most specialized and technically experienced RNAscope hands of any CRO
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.
ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.
In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics.
The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.